Open Demat Account

50years
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
left-arrow
Fundamentals
Financials
Shareholding
Resistance/Support
Delivery and Volume
About
Management
News
Similar Stocks
right-arrow

Dr Reddys Laboratories Ltd Performance

Today's Low
6,050.00
arrowIcon
Today's High
6,099.95
52 Wk Low
4,384.05
arrowIcon
52 Wk High
6,505.90


Open

6099.95

Traded Value (Cr)

66.80 Cr

Prev. Close

6050.35

VWAP

6037.03

Volume

4,08,298

Face Value

5

Dr Reddys Laboratories Ltd Fundamentals

Market Cap
₹ 1,02,894 Cr
P/E Ratio (TTM)
19.68
P/B Ratio
4.04
Debt to Equity
0.05
ROE
19.97 %
EPS (TTM)
313.41
Dividend Yield
0.65%
Book Value
1,528.42

Click here to know more about Fundamentals

Dr Reddys Laboratories Ltd F&O

Dr Reddys Laboratories Ltd Option Chain

Dr Reddys Laboratories Ltd Financials

Dr Reddys Laboratories Ltd Financials

Dr Reddys Laboratories Ltd Shareholding Pattern

Held By Dec 2023 Sep 2023 Jun 2023 Mar 2023
FII 28.62 % 28.20 % 27.00 % 27.25 %
Others 28.06 % 28.63 % 29.49 % 28.59 %
Promoters 26.65 % 26.66 % 26.69 % 26.70 %
Retail 8.44 % 7.91 % 7.51 % 7.59 %
Mutual Funds 8.22 % 8.61 % 9.31 % 9.87 %

FII

28.62%

Others

28.06%

Promoters

26.65%

Retail

8.44%

Mutual Funds

8.22%

FII

28.20%

Others

28.63%

Promoters

26.66%

Retail

7.91%

Mutual Funds

8.61%

FII

27.00%

Others

29.49%

Promoters

26.69%

Retail

7.51%

Mutual Funds

9.31%

FII

27.25%

Others

28.59%

Promoters

26.70%

Retail

7.59%

Mutual Funds

9.87%

Resistance and Support

₹6,114.73

PIVOT

resistance-arrow
Resistance
First Resistance₹6,169.467
Second Resistance₹6,210.733
Third Resistance₹6,265.467
support-arrow
Support
First Resistance₹6,073.467
Second Resistance₹6,018.733
Third Resistance₹5,977.467
RSI39.866
MACD-62.040
ADX18.400
CCI-144.606

Delivery and Volume

PeriodDelivery Volume Traded Volume Delivery Volume %
Day408,298241,73059.20
Week317,292243,58871.56
1 Month303,629157,41053.78
6 Months269,933269,933100.00

About Dr Reddys Laboratories Ltd

Dr Reddys Laboratories Ltd Share Price 

Dr. Anji Reddy founded Dr. Reddy's Laboratories in 1984 in Hyderabad, India, with an initial capital of ₹25 lakh. After starting to produce Active Pharmaceutical Ingredients and Intermediates (APIs), the business introduced methyldopa to the global market. The USFDA originally approved the company's Ibuprofen API in 1987. In 1991, the company began producing Omeprazole, a popular drug. In 1993, Dr. Reddy's Research Foundation focused on drug discovery for cancer and diabetes. In 1998, the company started biologics to offer affordable medicine to Indian consumers. In 2003, Ibuprofen was launched under their label in the US. In 2019, the company entered the nutrition segment in India with Celevida. Keep track of Dr. Reddy’s Laboratories share price with BlinkX. Dr Reddy share price history in India is characterised by oscillations caused by a variety of factors, including changes in the global energy environment, regulatory measures, and market demand.

Key Personnel of Dr. Reddy’s Laboratories

Erez Israeli, CEO

Erez Israeli, with an MBA from Bar-Ilan University and over 30 years of experience, became CEO of Dr. Reddy's Laboratories in July 2019. He previously held positions at Enzymotec and Teva Pharmaceuticals, specialising in sales and marketing.

G V Prasad, Co-chairman and MD

Mr. Prasad, who joined Dr. Reddy in 1990, has overseen the company's growth from a small domestic operation to a major global pharma brand, focusing on research, innovation, and corporate ethics.

Business Segment Dr. Reddy's Laboratories

Dr. Reddy's Global Presence and Business Overview

  • Generics, biosimilars, differentiated formulations, Active Pharmaceutical Ingredients (APIs), bespoke pharmaceutical services, and more are all provided by Dr. Reddy's Laboratories.
  • Focuses on gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.
  • Europe, Russia, India, and the United States are important markets.
  • Primary businesses include pharmaceutical services and active ingredients production, global generic drug production, and proprietary products.
  • As of March 2023, the company had 40 subsidiaries abroad and 9 in India.

BlinkX allows you to follow the Dr Reddy share price on the NSE and BSE on a daily basis.

Financial Highlights of Dr. Reddy’s Laboratories

  • The company's sales revenue increased by more than 100% from March 2013 to March 2023.
  • On the other hand, the company's net earnings increased by around 200% in the same period.
  • The net cash flows of the corporation have fluctuated during the past several years. After being negative for a few years, it increased to ₹1,286 crore in FY 2021; however, it dropped to ₹3 in FY 2022 and even lower to -₹907 crore in FY 2023.

Managing Director

G V Prasad

Founded

1984

NSE Symbol

DRREDDY

Dr Reddys Laboratories Ltd Management

NameDesignation
G V PrasadCo-Chairman & Managing Directo
K Satish ReddyExecutive Chairman
Kalpana MorpariaIndependent Director
Shikha Sanjaya SharmaIndependent Director
Leo PuriIndependent Director
K P KrishnanIndependent Director
Pennv WanIndependent Director
K Randhir SinghCompany Sec. & Compli. Officer
Arun M. KumarIndependent Director
Claudio AlbrechtIndependent Director

Dr Reddys Laboratories Ltd News

Dr. Reddy’s Lab arm launches migraine management device, Nerivio in Europe
Dr. Reddy’s Laboratories said that it has announced the launch of the drug-free non-invasive migraine management wearable device, Nerivio in Germany through its step-down subsidiary betapharm.
Dr Reddys launches migraine management wearable device Nerivio® in Germany
Dr. Reddy's Labs partners with Bayer for second brand of Vericiguat for India market
Dr.Reddy's Laboratories said entered into a partnership agreement with Bayerto market and distribute a second brand of Vericiguat in India.
Dr Reddys and Bayer partner to market and distribute second brand of Vericiguat in India
Dr Reddy’s rises on distribution partnership with Sanofi Healthcare
Dr Reddy's Laboratories gained 1.93% to Rs 6164.10 after the company said that it has entered into an exclusive partnership with Sanofi Healthcare India (SHIPL) to promote and distribute SHIPL vaccine brands across private markets in India.
Dr. Reddy's Lab enters into marketing licensing agreement with Pharmazz for Centhaquine
Dr. Reddy's Laboratories said that it has entered into a license agreement with Pharmazz Inc. to commercialise the first-in-class innovative drug Centhaquine in India.
Dr Reddys Laboratories to convene board meeting
On 7 May 2024
Dr Reddys Laboratories enters into license agreement with Pharmazz
To develop and commercialise Centhaquine in India
Dr Reddy’s Labs launches Versavo drug in UK
Dr Reddy’s Laboratories said that it has launched Versavo in the United Kingdom (UK) for the treatment of several types of cancers.
Dr. Reddy's launches Versavo® (bevacizumab) in UK
Used in treatment of several types of cancers

Similar Stocks

CompanyMarket CapMarket PriceP/E Ratio
SUNPHARMA₹ 3,68,909 Cr
₹ 1,534.65
(-0.19 %)
89.51
CIPLA₹ 1,11,029 Cr
₹ 1,372.95
(-0.16 %)
33.78
DIVISLAB₹ 99,927 Cr
₹ 3,743.60
(-0.55 %)
73.27
ZYDUSLIFE₹ 95,074 Cr
₹ 938.95
(-0.62 %)
35.39
MANKIND₹ 91,376 Cr
₹ 2,346.75
(2.88 %)
55.39

Dr Reddys Laboratories Ltd FAQ

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Dr Reddys Laboratories Ltd shares in BlinkX

The share price of any stock is volatile and changes during the day due to a variety of variables. Dr Reddys Laboratories Ltd's share price is ₹6,063.05 as of April 18, 2024

Dr Reddys Laboratories Ltd's P/E ratio is 19.68 times as of April 18, 2024.

Dr Reddys Laboratories Ltd's most recent financial reports indicate a price-to-book ratio of 4.04, showing the company's stock market valuation in relation to the value of its real assets.

Market capitalisation, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Dr Reddys Laboratories Ltd's market is 102,894 Cr as on April 18, 2024.

The current financial records of Dr Reddys Laboratories Ltd show a 19.97% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.

The 52-week high/low price of a Dr Reddys Laboratories Ltd stock is the highest and lowest price at which it has traded over that period (about one year) and is used as a technical indicator. Dr Reddys Laboratories Ltd's 52-week high and low as of April 18, 2024 are ₹6099.95 and ₹6050 respectively.

As of the Dec 2023 quarter, the promoter shareholding in Dr Reddys Laboratories Ltd stands at 26.65%. During the same period, Institutional Investors have shown a slight increase in their holdings, rising from 28.20% to 28.62%.